Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
1244: Efficacy of CAR T-cell and bispecific T-cell engager therapies for immune thrombocytopenia (ITP) secondary to hematologic malignancy	Saarang Deshpande, MD	5:30 - 7:30 p.m. MCCNO - Hall F
1434: Splicing factor dysfunction in myeloid malignancies causes a specific DNA repair defect and an opportunity for a novel targeted therapy	Shuhei Asada, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
1475: Targeted degradation of BTK, HCK, and LYN by a novel PROTAC DFCI-002-06 suppresses compensatory survival signaling and enhances FLT3 inhibitor activity in FLT3-ITD acute myeloid leukemia	John Hatcher, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
1508: Targeting compensatory signaling associated with acquired kinase dead BTK mutations in MYD88 mutated lymphoma cells	Shirong Liu, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
1737: Transcription factor networks critical for Waldenström's macroglobulinemia cells: Functional characterization and therapeutic implications	Torsten Steinbrunn, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
1744: Multiclonality underlies Waldenström macroglobulinemia associated with familial predisposition and inheritance of the chromosome 14 single nucleotide polymorphism (rs117972357)	Alberto Guijosa, MD	5:30 - 7:30 p.m. MCCNO - Hall F
1760: HLA-e expression stratifies cellular networks within the DLBCL microenvironment	Cynthia Hahn, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
1816: Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma and marginal zone lymphoma: Results of a multicenter phase 2 trial	Reid Merryman, MD	5:30 - 7:30 p.m. MCCNO - Hall F
1836: Distress is associated with inferior pre-treatment health-related quality of life among patients with PTCL: A cross-sectional analysis from the PETAL consortium	Ijeoma Julie Eche-Ugwu, PhD, MPH, FNP-BC, AOCNP, CPHON, TCT-CN	5:30 - 7:30 p.m. MCCNO - Hall F
1890: Comparative effectiveness of belinostat and romidepsin in relapsed/refractory nodal PTCL: Advanced statistical and machine learning analysis from the PETAL consortium	Mark Sorial, PharmD	5:30 - 7:30 p.m. MCCNO - Hall F
2143: Initial results of phase 1b cohort of roginolisib (IOA-244), an orally bioavailable, conformation-selective PI3Kd inhibitor, in combination with venetoclax and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)	Jennifer Brown, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
2152: CD3+ T cells from high-risk smoldering multiple myeloma preserve functional competence driving greater teclistamab-mediated cytotoxicity compared to later stages	Anushka Ghosh, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
2160: Longitudinal single-cell RNA sequencing reveals reversible plasma cell reprogramming but persistent M2 macrophage polarization following daratumumab-based therapy in AL amyloidosis	Jackson Smith, MSc	5:30 - 7:30 p.m. MCCNO - Hall F
2163: The RNA helicase DHX9 couples RNA metabolism to genome maintenance and defines an actionable therapeutic vulnerability in multiple myeloma	Harshini Sriram, PhD	5:30 - 7:30 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
2198: Biochemical progression in treated high-risk smoldering myeloma predicts progression to active multiple myeloma: A pooled analysis of 9 prospective clinical trials	Tarek Mouhieddine, MD	5:30 - 7:30 p.m. MCCNO - Hall F
2204: Single-cell immune profiling reveals distinct baseline immune features associated with deep clinical responses to Dara-RVD in patients with high-risk smoldering multiple myeloma	Nayda Bidikian, MD	5:30- 7:30 p.m. MCCNO - Hall F
2242: Selinexor, mezigdomide, and dexamethasone (SMd) in patients with relapsed/refractory multiple myeloma (RRMM) who relapsed or are ineligible for T-cell-redirecting therapy: Updated results from STOMP arm 12	Clifton Mo, MD	5:30 - 7:30 p.m. MCCNO - Hall F
2245: Trial in progress: Determination 2, a phase 3 trial evaluating risk-adapted and response-adapted treatment strategies in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM)	Clifton Mo, MD	5:30 - 7:30 p.m. MCCNO - Hall F
2290: Consensus genomic staging extends to smoldering myeloma, identifying patients at risk of progression and complements the 20/2/20 risk model	Mehmet Kemal Samur, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
2257: Real-world effectiveness of teclistamab versus standard triplet therapy in relapsed/refractory multiple myeloma: A propensity Score-Matched trinetx study	Zeeshan Solangi, MD	5:30 - 7:30 p.m. MCCNO - Hall F
2276: Cumulative infection burden predicts inferior survival during BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma	Ariel Siegel, MD	5:30 - 7:30 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
2559 Machine learning-based structural prediction studies inform the identification of "druggable" pockets in previously understudied myeloma-preferential dependencies	Evangelos Papadopoulos	5:30 - 7:30 p.m. MCCNO - Hall F
2566: A replicable framework for digitalization and integration of a large-scale, multi-protocol cryopreserved biobank: Application to monoclonal gammopathy precursor research	Ana Batlle Lopez, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
2567: Systematic integration of enriched surface proteomics with transcriptomics identifies novel targets in AML	Benson George, MD, PhD	5:30 - 7:30 p.m. MCCNO - Hall F
2655: Patient perspectives about artificial intelligence in hematology and oncology: An interim analysis	Eric Blackstone, PhD, HEC-C	5:30 - 7:30 p.m. MCCNO - Hall F
2810: Real world clinical outcomes in patients with essential thrombocythemia with vs without resistance or intolerance to hydroxyurea	Evan Chen, MD	5:30 - 7:30 p.m. MCCNO - Hall F
2820: Does pre-existing depression or anxiety preclude ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia?: A real-world multicenter cohort study	Katherine Feder, MD, MS	5:30 - 7:30 p.m. MCCNO - Hall F
2836: Endothelial activation and stress index (EASIX) score explored as a potential early indicator of capillary leak syndrome (CLS) during tagraxofusp (TAG) treatment for patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Subgroup analysis of a pivotal trial	Shai Shimony, MD, MPH	5:30 - 7:30 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Sunday, December 13, 2026		
3147: Paracrine protection of myelopoiesis by bone marrow CD37+ macrophage-like myeloid suppressor cells during inflammatory stress	Alexandra Pommier, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
3267: Development of a novel, second generation dual IRAK1/IRAK4 proteolysis targeting chimera (DFCI-001-149) that is highly active in MYD88 mutated lymphoma cells including those with clinically relevant BTK mutations	John Hatcher, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
3282: Socioeconomic disadvantage is associated with worse event-free survival and higher relapse rates in adolescents and younger adults with acute lymphoblastic leukemia treated with pediatric-inspired regimens	Melanie Wendy Castro Mollo, MD	6:00 - 8:00 p.m. MCCNO - Hall F
3403: Revumenib in real-world practice for relapsed/refractory acute leukemia: Second interim findings from the multicenter ROAR study	Shai Shimony, MD, MPH	6:00 - 8:00 p.m. MCCNO - Hall F
3427: Transient and manageable tagraxofusp (TAG)-associated hepatic abnormalities, without on-treatment veno-occlusive disease (VOD), in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN): R-value subgroup analysis of the pivotal trial	Andrew Lane, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
3507: Chromosome 6q loss cooperates with MYD88L265P to drive lymphoplasmacytic lymphoma and its progression to diffuse large B-cell lymphoma	Filip Garbicz, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
3548: Defining the clinical, genomic, and therapeutic landscape of non-IgM lymphoplasmacytic lymphoma	Alberto Guijosa, MD	6:00 - 8:00 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Sunday, December 13, 2026		
3581: Efficacy of PD-1 maintenance after autologous stem cell transplantation in relapsed/ refractory classic Hodgkin lymphoma: Long-term follow-up of two phase 2 trials and a propensity-score matching analysis	Reid Merryman, MD	6:00 - 8:00 p.m. MCCNO - Hall F
3863: The TBX21-ZNF683 T-cell axis orchestrates natural control of chronic lymphocytic leukemia	Marwan Kwok, MD, PhD, MRCP, FRCPath	6:00 - 8:00 p.m. MCCNO - Hall F
3879: CLL-MPI: Development of a molecular prognostic index in chronic lymphocytic leukemia assisted by machine learning	Daniel Sungchul Choi, MD	6:00 - 8:00 p.m. MCCNO - Hall F
3910: Safety and tolerability of a simplified ramp-up schedule of sonrotoclax in combination with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (TN CLL): initial results from a phase 1 global study	Matthew Davids, MD, MMSc	6:00 - 8:00 p.m. MCCNO - Hall F
3947: Spatial transcriptomics reveal T-cell engagement without tumor clearance in teclistamab resistance in multiple myeloma	Yao Yu Yeo, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
3956: Machine learning-derived blood-based immune signatures stratify progression risk in precursors of multiple myeloma	Nayda Bidikian, MD	6:00 - 8:00 p.m. MCCNO - Hall F
3957: Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy	Shayna Sarosiek, MD	6:00 - 8:00 p.m. MCCNO - Hall F
4146: TGF-ß sensing CD70 CAR-NK cells armed with inducible IL-12 and constitutive IL-18 overcome microenvironmental suppression in AML	Fuguo Liu, PhD	6:00 - 8:00 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Sunday, December 13, 2026		
4151: Tumor cells with compromised antigen presentation machinery: Mechanistic insights into resistance vs. sensitization to NK cells through CRISPR-based functional genomics studies	Olga Dashevsky, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
4153: Successful generation of NK and NKT-like cells from AML patient PBMCs for autologous bone marrow-homing cellular immunotherapy	Evan Chen, MD	6:00 - 8:00 p.m. MCCNO - Hall F
4229: Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after reduced-intensity mismatched unrelated donor peripheral blood stem cell transplantation: 2-year outcomes from the ACCESS trial	Mahasweta Gooptu, MD	6:00 - 8:00 p.m. MCCNO - Hall F
4392: Foundational abstraction of lymphoma clinical study-relevant features from medical notes using large language models	Emma Pranschke, MPH	6:00 - 8:00 p.m. MCCNO - Hall F
4455: Characterization of skin cancer in patients with SMAD4 mutation in hereditary hemorrhagic telangiectasia: Risk assessment for a rare genetic vasculopathy	Ruhi Kanwar, MD	6:00 - 8:00 p.m. MCCNO - Hall F
4521: Estimating clinically meaningful change thresholds for a European organisation for research and treatment of cancer IL- 409 proxy in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial	Jennifer Brown, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
4582: Evaluating thrombotic risk and hematocrit response from intravenous iron repletion in cytoreduced patients with polycythemia vera	Katherine Feder, MD, MS	6:00 - 8:00 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Monday, December 14, 2026		
5260: Familial Waldenstrom's macroglobulinemia is associated with a highly prevalent SNP in Chr14q (rs117972357) and expression of HLA-DRB5	Zachary Hunter, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
5279: Post-translational control of HLA-e is a targetable strategy to overcome immune escape in DLBCL	Minjae Song	6:00 - 8:00 p.m. MCCNO - Hall F
5290: Discovery of a highly aberrant CCR1-driven CD54+ classical monocytes driving MDSC-like function in Waldenström's macroglobulinemia	Hao Sun, MD, PhD,	6:00 - 8:00 p.m. MCCNO - Hall F
5296: Phase 2 study combining fixed duration pirtobrutinib and venetoclax in previously treated Waldenström macroglobulinemia	Jorge Castillo, MD	6:00 - 8:00 p.m. MCCNO - Hall F
5313: Supervised machine learning algorithms identify baseline features that predict infection in patients with follicular lymphoma receiving frontline epcoritamab	Siri Sagedahl, BA	6:00 - 8:00 p.m. MCCNO - Hall F
5324: Switching ibrutinib to zanubrutinib in Waldenström macroglobulinemia: Tolerability and outcomes in 87 patients	Nicolò Danesin, MD	6:00 - 8:00 p.m. MCCNO - Hall F
5632: Defining the landscape of shared canonical and noncanonical HLA-I antigens in CLL	Marijn Bakker	6:00 - 8:00 p.m. MCCNO - Hall F
5641: Alliance A042302: Phase 3 evaluation of fixed duration zanubrutinib plus sonrotoclax-based therapy compared to continuous zanubrutinib in previously untreated older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)	Jennifer Brown, MD, PhD	6:00- 8:00 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Monday, December 14, 2026		
5644: Serum monoclonal immunoglobulin associates with high-risk genomic and clinical features in chronic lymphocytic leukemia	Uday Aditya Sarkar, PhD	6:00- 8:00 p.m. MCCNO - Hall F
5671: A Phase 2 study of zanubrutinib and venetoclax (ZV) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)	Inhye Ahn, MD	6:00 - 8:00 p.m. MCCNO - Hall F
5674: Efficacy of frontline combination targeted therapy in chronic lymphocytic leukemia with highly complex karyotype: A retrospective analysis	Kiyomi Mashima, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
5678: A single-nucleotide atlas of the epitranscriptome reveals METTL3-dependent therapeutic vulnerabilities in multiple myeloma	Laure Vreux, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
5777: A phase 1, open-label study to evaluate the efficacy and safety of elotuzumab in combination with iberdomide post-idecabtagene vicleucel in participants with relapsed and refractory multiple myeloma	Shonali Midha, MD	6:00 - 8:00 p.m. MCCNO - Hall F
5781: Comparative effectiveness of mezigdomide + carfilzomib + dexamethasone (MeziKd) versus real-world standard of care (SoC) in lenalidomide and anti-CD38-exposed RRMM: a population-adjusted indirect comparison	Paul Richardson, MD	6:00 - 8:00 p.m. MCCNO - Hall F
5899: Spatially restricted CAR T-cell inflammatory niches disrupt granulopoiesis and contribute to hematotoxicity	David Manuel Cordas Dos Santos, MD	6:00 - 8:00 p.m. MCCNO - Hall F

Dana-Farber Cancer Institute

Poster Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Monday, December 14, 2026		
5909: ADA-displaying non-pathogenic e. coli overcome adenosine-mediated immunosuppression and remodel the immunometabolic environment in AML	Stephanie Sendker, MD	6:00 - 8:00 p.m. MCCNO - Hall F
6008: Donor DNMT3A mutations impact dynamics of immune reconstitution in allogeneic stem cell transplant recipients	Francesco Malfona, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
6009: Somatic mosaicism drives tissue-specific allorecognition in cutaneous graft-versus-host disease along blaschko lines	Nicoletta Cieri, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
6114: Digital pathology modeling improves disease progression prediction and identifies histologic biomarkers in multiple myeloma precursor neoplasms	Joshua Lewis, MD, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
6117: Single-cell spatial proteomic characterization of the multiple myeloma bone marrow microenvironment identifies altered cell surface architecture with disease progression	Arghya Ray, PhD	6:00 - 8:00 p.m. MCCNO - Hall F
6184: Interim analysis of a feasibility and usability study for trial, a disease and clinical trial education and resource connection application for patients with newly diagnosed acute leukemia	Andrew Hantel, MD, MPH	6:00 - 8:00 p.m. MCCNO - Hall F
6210: The association between hereditary hemorrhagic telangiectasia and skin cancer: A retrospective cohort study	Ruhi Kanwar, MD	6:00 - 8:00 p.m. MCCNO - Hall F